Melanoma Clinical Trials

Showing 461-480 of 1,260 trials

Dermoscopy and Histopathology in Non-melanocytic Skin Tumors

NCT06523816

The main aim of the study is to investigate the relation between dermoscopic findings in pre-operative diagnosis of non-melanocytic skin tumors and post-operative histopathology findings .

Non-melanoma Skin Cancer

Assiut University20 participantsStarted Oct 2024

TERMINATEDPhase 1/2

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

NCT04198818

This is a First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors, composed of a Phase I dose escalation and dose expansion stage and a Phase II dose extension stage.

Advanced TumorsMelanomaNon-Small-Cell Lung Cancer+2 more

Haihe Biopharma Co., Ltd.37 participantsStarted Jan 2020

Lafayette, Indiana, United States • Detroit, Michigan, United States • Shanghai, China

Active Not RecruitingPhase 1

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

NCT03552718

This is a phase 1 study to evaluate the safety, the Recommended Phase 2 Dose (RP2D), and preliminary efficacy of a personalized neoepitope yeast-based vaccine, YE-NEO-001, in subjects who have completed potentially curative therapy for their solid cancer and who would otherwise be entering a period of surveillance for recurrent disease.

Colorectal CancerBreast CancerHead and Neck Squamous Cell Carcinoma+4 more

NantBioScience, Inc.16 participantsStarted Aug 2018

El Segundo, California, United States

Dermoscopy and Histopathology in Non-melanocytic Skin Tumors

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

Related Searches

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases

PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy

LATe TreatmENT Related Toxicity in Melanoma (LATENT)

Dermoscopy Augmented Histology Trial, a Randomized Controlled Trial

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)

Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma

Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

PD-L1 PET Imaging in Melanoma Patients

Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases